France Hematopoietic Stem Cell Transplantation Market

ID: MRFR/LS/48280-HCR
200 Pages
Nidhi Mandole
Last Updated: April 24, 2026
France Hematopoietic Stem Cell Transplantation Market Research Report: Size, Share, Trend Analysis By Transplant Type (Allogeneic, Autologous), By Indication (Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Other Non-Malignant Disorders) and By Applications (Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, Cord Blood Transplant) - Growth Outlook & Industry Forecast 2025 To 2035
France Hematopoietic Stem Cell Transplantation Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)12.06%
2024 Market Size$ 200.1 Million
2025 Market Size$ 224.23 Million
2035 Market Size$ 700 Million
Key Players
Novartis
Bristol-Myers Squibb
Amgen
Gilead Sciences
Celgene
Takeda Pharmaceutical
Trends
  • Increasing Demand for Stem-Cell Therapies
  • Advancements in Regulatory Frameworks
  • Emphasis on Personalized Medicine
Opportunities
  • Government Initiatives and Funding
  • Growing Awareness and Patient Advocacy
  • Rising Incidence of Hematological Disorders
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Industrial Automation & Equipment, BY Transplant Type (USD Million)
      1. 4.1.1 Allogeneic
      2. 4.1.2 Autologous
    2. 4.2 Industrial Automation & Equipment, BY Indication (USD Million)
      1. 4.2.1 Acute Myeloid Leukemia
      2. 4.2.2 Acute Lymphoblastic Leukemia
      3. 4.2.3 Hodgkin Lymphoma
      4. 4.2.4 Non-Hodgkin Lymphoma
      5. 4.2.5 Multiple Myeloma
      6. 4.2.6 Other Non-Malignant Disorders
    3. 4.3 Industrial Automation & Equipment, BY Application (USD Million)
      1. 4.3.1 Bone Marrow Transplant
      2. 4.3.2 Peripheral Blood Stem Cells Transplant
      3. 4.3.3 Cord Blood Transplant
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novartis (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Amgen (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Gilead Sciences (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Celgene (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Takeda Pharmaceutical (JP)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Roche (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Merck & Co. (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 AstraZeneca (GB)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 FRANCE MARKET ANALYSIS BY TRANSPLANT TYPE
    3. 6.3 FRANCE MARKET ANALYSIS BY INDICATION
    4. 6.4 FRANCE MARKET ANALYSIS BY APPLICATION
    5. 6.5 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
    8. 6.8 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    10. 6.10 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
    11. 6.11 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TRANSPLANT TYPE, 2024 (% SHARE)
    12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TRANSPLANT TYPE, 2024 TO 2035 (USD Million)
    13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY INDICATION, 2024 (% SHARE)
    14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY INDICATION, 2024 TO 2035 (USD Million)
    15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION, 2024 (% SHARE)
    16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TRANSPLANT TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY INDICATION, 2025-2035 (USD Million)
      3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

France Hematopoietic Stem Cell Transplantation Market Segmentation

France Hematopoietic Stem Cell Transplantation Market By Transplant Type (USD Million, 2025-2035)

  • Allogeneic
  • Autologous

France Hematopoietic Stem Cell Transplantation Market By Indication (USD Million, 2025-2035)

  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • Multiple Myeloma
  • Other Non-Malignant Disorders

France Hematopoietic Stem Cell Transplantation Market By Application (USD Million, 2025-2035)

  • Bone Marrow Transplant
  • Peripheral Blood Stem Cells Transplant
  • Cord Blood Transplant

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.